Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Acton

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Bioorganic & Medicinal Chemistry Letters|July 12, 2008
Imidazole piperazines: SAR and development of a potent class of cyclin-dependent kinase inhibitors with a novel binding modeM Raymond V Finlay, David G Acton, David M Andrews, et al.
Bioorganic & Medicinal Chemistry Letters|July 26, 2011
Small-molecule androgen receptor downregulators as an approach to treatment of advanced prostate cancerRobert H Bradbury, Neil J Hales, Alfred A Rabow, et al.
Pediatric Blood & Cancer|December 2, 2016
A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemiaB Vormoor, G J Veal, M J Griffin, et al.
Bioorganic & Medicinal Chemistry Letters|March 8, 2013
Discovery of AZD3514, a small-molecule androgen receptor downregulator for treatment of advanced prostate cancerRobert H Bradbury, David G Acton, Nicola L Broadbent, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Bioorganic & Medicinal Chemistry Letters|July 12, 2008
Imidazole piperazines: SAR and development of a potent class of cyclin-dependent kinase inhibitors with a novel binding modeM Raymond V Finlay, David G Acton, David M Andrews, et al.
Bioorganic & Medicinal Chemistry Letters|July 26, 2011
Small-molecule androgen receptor downregulators as an approach to treatment of advanced prostate cancerRobert H Bradbury, Neil J Hales, Alfred A Rabow, et al.
Pediatric Blood & Cancer|December 2, 2016
A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemiaB Vormoor, G J Veal, M J Griffin, et al.
Bioorganic & Medicinal Chemistry Letters|March 8, 2013
Discovery of AZD3514, a small-molecule androgen receptor downregulator for treatment of advanced prostate cancerRobert H Bradbury, David G Acton, Nicola L Broadbent, et al.
Pageof 2